Professor of Medicine University of California Irvine Laguna, California
Learning Objectives:
Assess the current treatment options for CLL beyond the current chemoimmunotherapy (CIT) standard
Explain the genetic characteristics of CLL/SLL, including 17p deletions, and how gene mutation status affects patient outcomes in response to targeted therapies
Evaluate the mechanism of action, safety/efficacy data, and potential drug-drug interactions associated with major emerging agents, including Anti CD-20 mABs, BCL-2 inhibitors, and BTK inhibitors
Incorporate patient preference and AE management strategies into patient-centered treatment decisions